Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.72% and +50.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?